In a nutshell
This study investigated the effectiveness of pimavanserin (PVS; Nuplazid) in the treatment of sleep disorders in patients with Parkinson’s disease. Researchers suggested that PVS improves the quality of sleep of these patients.
Some background
Most patients with Parkinson’s disease have some manner of night-time sleep disorder or daytime sleepiness. Sleep complications are associated with the increase of other mental symptoms. This affects daily routines and the quality of life of patients and their caregivers. Furthermore, patients with sleep symptoms are 5 times more at risk of having psychosis (hallucinations or delusions).
Pimavanserin (PVS) has been used to treat psychosis in patients with Parkinson's disease. Prior studies suggested that PVS could also help in the treatment of sleep disorders. However, it is still not clear if PVS is a safe option in the treatment of both night-time sleep and daytime sleepiness.
Methods & findings
This study included information about 374 patients with Parkinson's disease from 2 different trials. These patients were divided into 2 groups. One group received 34 mg of PVS and the other group received a placebo. Questionnaires were used to evaluate sleep-related disorders and quality of life.
After 4 and 6 weeks of treatment, PVS was associated with an improved night-time sleep when compared to the placebo group. PVS was also associated with improvements in daytime sleepiness, particularly in patients who has improvements in psychosis symptoms.
The bottom line
This study showed that pimavanserin treatment is associated with an improved night-time sleep in patients with Parkinson’s disease.
The fine print
The results from this study showed only short-term responses to PVS. Also, the information came from two different trials with different protocols. Further studies are needed.
Published By :
Clinical neuropharmacology
Date :
Oct 09, 2018
